Vidofludimus calcium currently is being evaluated in relapsing MS in two phase III trials, ENSURE-1 and ENSURE-2. The phase ...

Patients with primary progressive MS more commonly exhibited delays in overall disability progression following treatment with ocrelizumab vs placebo.

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

New research identifies biomarkers in people with radiologically isolated syndrome (RIS) that better predict who will develop ...

For decades, multiple sclerosis (MS) research has focused largely on the inflammatory lesions visible on MRI scans. Yet new ...

In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before disability worsened between people taking certain medications and those not ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Multiple ...

A new FDA target action date of 28 December could bring tolebrutinib’s tumultuous development period to an end.

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...

Treatment of primary progressive multiple sclerosis (PPMS) with disease-modifying therapies (DMTs) for patients experiencing relapse or with disease activity is linked to a significant reduction of ...

The company was expecting a decision from the FDA by Sept. 28 for its oral drug tolebrutinib, but an update to the drug’s ...